Genomic loci for this biosynthetic pathway

Cluster Type From To
The following clusters are from record BGC0000206.1:
Cluster 1Polyketide119580
The following clusters are from record BGC0000206.2:
Cluster 2Polyketide117540

BGC0000206, chartreusin biosynthetic gene cluster from Streptomyces chartreusis. Locus 1. Full MIBiG entry.

Chemical compounds

Compound: chartreusin
PubChem ID: 5281394
ChemSpider ID: 4444748
SMILES string: Copy to clipboard
Molecular formula: C32H32O14
Average molecular mass: 640.594 Da
Molecular activity: Inhibitor, Other
Molecular target: DNA, topoisomerase II

Class-specific details

Biosynthetic class(es):
Polyketide
Polyketide subclass:
Anthracycline (cyclic)
Polyketide synthase subclass:
Type II
Starter unit:
Acetyl-CoA
Polyketide synthase / ketosynthase-encoding genes:
CAH10161.1
Genes involved in folding/cyclization:
CAH10155.1, CAH10156.1

Gene cluster description

chartreusin (BGC0000206). Gene Cluster 1. Biosynthetic class = Polyketide. GenBank AJ786382. Click on genes for more information.

Legend:

biosynthetic genes
transport-related genes
regulatory genes
other genes

Homologous known gene clusters

General MIBiG information on this cluster

Complete gene cluster sequence?complete
Evidence for cluster-compound connection:Knock-out studies, Heterologous expression, Sequence-based prediction
MIxS-compliance:Unknown
Contact for this cluster:Keishi Ishida (Leipniz Institute for Natural Product Research and Infection Biology)

Literature references

1. Xu Z et al. (2005) Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyketide. Chem Biol 12(5):579-88. doi: 10.1016/j.chembiol.2005.04.017.
2. Portugal J. (2003) Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr Med Chem Anticancer Agents 3(6):411-20.
3. Barcelo F et al. (2002) Thermodynamic characterization of the multivalent binding of chartreusin to DNA. Nucleic Acids Res 30(20):4567-73.
4. Asai G et al. (2002) Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemother Pharmacol 49(6):468-72. doi:

BGC0000206, chartreusin biosynthetic gene cluster from Streptomyces chartreusis. Locus 2. Full MIBiG entry.

Chemical compounds

Compound: chartreusin
PubChem ID: 5281394
ChemSpider ID: 4444748
SMILES string: Copy to clipboard
Molecular formula: C32H32O14
Average molecular mass: 640.594 Da
Molecular activity: Inhibitor, Other
Molecular target: DNA, topoisomerase II

Class-specific details

Biosynthetic class(es):
Polyketide
Polyketide subclass:
Anthracycline (cyclic)
Polyketide synthase subclass:
Type II
Starter unit:
Acetyl-CoA
Polyketide synthase / ketosynthase-encoding genes:
CAH10161.1
Genes involved in folding/cyclization:
CAH10155.1, CAH10156.1

Gene cluster description

chartreusin (BGC0000206). Gene Cluster 2. Biosynthetic class = Polyketide. GenBank AJ786383. Click on genes for more information.

Legend:

biosynthetic genes
transport-related genes
regulatory genes
other genes

Homologous known gene clusters

General MIBiG information on this cluster

Complete gene cluster sequence?complete
Evidence for cluster-compound connection:Knock-out studies, Heterologous expression, Sequence-based prediction
MIxS-compliance:Unknown
Contact for this cluster:Keishi Ishida (Leipniz Institute for Natural Product Research and Infection Biology)

Literature references

1. Xu Z et al. (2005) Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyketide. Chem Biol 12(5):579-88. doi: 10.1016/j.chembiol.2005.04.017.
2. Portugal J. (2003) Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr Med Chem Anticancer Agents 3(6):411-20.
3. Barcelo F et al. (2002) Thermodynamic characterization of the multivalent binding of chartreusin to DNA. Nucleic Acids Res 30(20):4567-73.
4. Asai G et al. (2002) Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemother Pharmacol 49(6):468-72. doi: